Urologic Health Raises $11 Million to Advance Noninvasive Bladder Diagnostics

Urologic Health announced in a press release that it has raised $11 million in seed financing to support clinical validation, regulatory approval, and initial commercialization of its noninvasive bladder function monitoring system. The round was led by an undisclosed strategic investor with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and other healthcare investors.

The company’s niu System captures bladder activity data without using catheters, offering a noninvasive alternative for assessing conditions such as overactive bladder, urinary retention, and incontinence. Early feasibility studies have shown that the system can record clinically meaningful bladder activity for diagnostic use.

Funds from the round will also support product and manufacturing development and the establishment of Urologic Health’s headquarters in Jersey City, New Jersey, as it prepares for U.S. market entry. The niu System remains limited to investigational use and has not yet received FDA clearance.